Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Xencor ( (XNCR) ) has provided an announcement.
On April 23, 2026, Xencor, Inc. adopted an Executive Severance Policy covering certain senior executives, including its named executive officers other than the chief executive. The policy provides that, if an eligible executive signs a participation agreement and is terminated without cause or resigns for good reason outside a change-in-control window, they are entitled to a lump-sum payment equal to 15 months of base salary and up to 15 months of paid COBRA premiums.
If an eligible executive experiences such a termination during a defined change-in-control period, the policy adds 15 months of target bonus, a prorated annual bonus, and accelerated vesting of all unvested stock options and equity awards. The move formalizes Xencor’s executive protections and could strengthen leadership retention and alignment during potential strategic transactions, with implications for governance and stakeholder confidence in periods of corporate change.
The most recent analyst rating on (XNCR) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on Xencor stock, see the XNCR Stock Forecast page.
Spark’s Take on XNCR Stock
According to Spark, TipRanks’ AI Analyst, XNCR is a Neutral.
The score is driven primarily by weak financial performance (sharp revenue decline to $0 in 2025, heavy losses, and ongoing cash burn). Technicals also remain bearish with negative momentum and price below key moving averages. Valuation is constrained by losses (negative P/E), and recent corporate events add uncertainty via collaboration and royalty headwinds, partially offset by stated liquidity runway.
To see Spark’s full report on XNCR stock, click here.
More about Xencor
Xencor, Inc. operates in the biopharmaceutical industry, focusing on the discovery and development of engineered monoclonal antibodies and other protein therapeutics. The company targets serious diseases, particularly in oncology and autoimmune conditions, using its proprietary XmAb technology platform to create differentiated drug candidates for global markets.
Average Trading Volume: 767,480
Technical Sentiment Signal: Sell
Current Market Cap: $951.9M
For an in-depth examination of XNCR stock, go to TipRanks’ Overview page.